Fintel reports that on November 22, 2024, B. Riley Securities initiated coverage of Viking Therapeutics (NasdaqCM:VKTX) with a Buy recommendation.
Analyst Price Forecast Suggests 127.63% Upside
As of November 21, 2024, the average one-year price target for Viking Therapeutics is $119.71/share. The forecasts range from a low of $95.95 to a high of $172.20. The average price target represents an increase of 127.63% from its latest reported closing price of $52.59 / share.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Viking Therapeutics is 1MM. The projected annual non-GAAP EPS is -1.13.
What is the Fund Sentiment?
There are 815 funds or institutions reporting positions in Viking Therapeutics. This is an increase of 64 owner(s) or 8.52% in the last quarter. Average portfolio weight of all funds dedicated to VKTX is 0.25%, an increase of 14.12%. Total shares owned by institutions increased in the last three months by 6.64% to 96,236K shares. 
The put/call ratio of VKTX is 0.33, indicating a bullish outlook.
What are Other Shareholders Doing?
BlackRock holds 5,380K shares representing 4.83% ownership of the company. In its prior filing, the firm reported owning 6,026K shares , representing a decrease of 12.00%. The firm decreased its portfolio allocation in VKTX by 1.10% over the last quarter.
FDGRX - Fidelity Growth Company Fund holds 3,737K shares representing 3.35% ownership of the company. In its prior filing, the firm reported owning 3,688K shares , representing an increase of 1.30%. The firm decreased its portfolio allocation in VKTX by 0.20% over the last quarter.
XBI - SPDR(R) S&P(R) Biotech ETF holds 3,472K shares representing 3.12% ownership of the company. In its prior filing, the firm reported owning 1,064K shares , representing an increase of 69.35%. The firm increased its portfolio allocation in VKTX by 123.50% over the last quarter.
VTSMX - Vanguard Total Stock Market Index Fund Investor Shares holds 3,319K shares representing 2.98% ownership of the company. In its prior filing, the firm reported owning 3,029K shares , representing an increase of 8.73%. The firm decreased its portfolio allocation in VKTX by 31.12% over the last quarter.
NAESX - Vanguard Small-Cap Index Fund Investor Shares holds 2,632K shares representing 2.36% ownership of the company. In its prior filing, the firm reported owning 1,227K shares , representing an increase of 53.38%. The firm increased its portfolio allocation in VKTX by 45.47% over the last quarter.
Viking Therapeutics Background Information
(This description is provided by the company.)
Viking Therapeutics is a clinical-stage biopharmaceutical company focused on the development of novel, orally available, first-in-class or best-in-class therapies for the treatment of metabolic and endocrine disorders. Viking's research and development activities leverage its expertise in metabolism to develop innovative therapeutics designed to improve patients' lives. The company's clinical programs include VK2809, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the treatment of lipid and metabolic disorders, which is currently being evaluated in a Phase 2b study for the treatment of biopsy-confirmed non-alcoholic steatohepatitis (NASH) and fibrosis. In a Phase 2 trial for the treatment of non-alcoholic fatty liver disease (NAFLD) and elevated LDL-C, patients who received VK2809 demonstrated statistically significant reductions in LDL-C and liver fat content compared with patients who received placebo. The company is also developing VK0214, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the potential treatment of X-linked adrenoleukodystrophy (X-ALD). VK0214 is currently being evaluated in a Phase 1 first-in-human clinical trial. The company holds exclusive worldwide rights to a portfolio of five therapeutic programs, including those noted above, which are based on small molecules licensed from Ligand Pharmaceuticals Incorporated.
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
